Drug intelligence / Profile preview

Azithromycin (Tibet Aim Pharm)

Development stage: Unknown
Lead developer: Tibet Aim Pharm
Modality: Small Molecules
Administration: Oral

Overview

Azithromycin is a macrolide antibiotic developed and marketed by Tibet Aim Pharm as an oral capsule formulation. It functions as a small molecule inhibitor of the bacterial 50S ribosomal subunit, thereby blocking bacterial protein synthesis. This product is approved in China for the treatment of various bacterial infections and is currently undergoing the regulatory consistency evaluation process (一致性评价) to ensure bioequivalence with the reference listed drug.

Brand names: 阿奇霉素胶囊
Other names: Azithromycin Capsules

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on Azithromycin (Tibet Aim Pharm).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azithromycin (Tibet Aim Pharm).

Explore the full profile